Citations 11

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940

10.1182/bloodadvances.2018018531 | PMID 29685953

Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.